Floatz logo

hbi0101 cart

Multiple Myeloma, Refractory to Standard Treatment

Hadassah Medical OrganizationCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Multiple Myeloma, Refractory to Standard Treatment cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

hbi0101 cart is also rated in:

AL amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →
systemic sclerosisDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →